Dear Sir, Non-classical congenital adrenal hyperplasia (NC-CAH) due to 21-hydroxylase deficiency is one of the most frequent autosomal recessive diseases, with an estimated prevalence of 1 in 1000. It may manifest at different stages in life. In late childhood, it may present with advanced skeletal maturation, accelerated growth or premature pubarche. In adult women, the disease usually presents with a hyperandrogenic syndrome including hirsutism, acne, androgenic alopecia, anovulation, menstrual dysfunction, and infertility. 1, 2 However, not all individuals with NCCAH are symptomatic and affected males are not usually detected until a female family member is diagnosed. 1, 2 Individuals with NCCAH may be compound heterozygotes and can carry severe CYP21A2 allele mutations. 2 Consequently, genetic testing and counseling is highly recommended when planning pregnancy. Our aim was to assess CYP21A2 allele mutations and review the clinical characteristics in patients with a NCCAH diagnosis attended at the center, irrespective of their need for genetic counseling at short term.
Patients with a diagnosis of NCCAH were recruited when they came for their regular follow-up visits. Medical records were examined to retrieve data about initial clinical presentation, later signs and symptoms, hormonal work-up [basal and stimulated 17-hydroxyprogesterone (17OHP)], and treatment at diagnosis and follow-up. A standardized database was used. The interpretation of the patients' hormonal work-up was performed according to Speiser PW et al: basal 17OHP 6 and <30 nmol/L was considered abnormal, while basal or stimulated 17OHP 30 and <300 nmol/l was considered indicative of NCCAH. 3 Analysis of the CYP21A2 gene was performed through polymerase chain reaction, sequencing, and family genetic testing when possible. 4 Data obtained from descriptive statistic analysis is expressed as percentages and medians (interquartile range). Chi-square and Mann-Whitney tests were used for comparisons among groups. The Institutional Review Board gave special approval for the study.
Results are summarized in Table 1 . The audit included 29 women followed at the Pediatrics (N=5), Gynecology & Obstetrics (N= 6) or Endocrinology & Nutrition (N= 18) Departments at our center. The initial clinical diagnosis was made in all of these departments, as well as in the Endocrinology Departments of other centers from 1976 to 2010. Twenty-four patients (82.7%) were index cases. Age at first symptom was 15.8 ± 8 years and the median number of symptoms was 2 (1 to 3). The most common manifestations were hirsutism (69%) and oligomenorrhea (48.3%). Basal 17OHP at diagnosis was available in the clini- Genetic analysis is summarized in Table 1 . Genetic testing of parents or siblings was performed in 10 patients (34.5%) to clarify the genetic diagnosis. The most common mutation (28 out of 45, 62%) was one that is known to be mild: Val281Leu. Globally, 37.9% of the genetic results did not confirm the alleged diagnosis. Other genes were not analyzed, but since 95% of cases are due to a mutation of the CYP21A2 gene, 3 it is unlikely that more than one third of the women had a mutation in a different gene.
The rate of non-confirmatory genetic analysis was not significantly different in women with a satisfactory biochemical diagnosis of NCCAH (33.1%) vs those without (50%). Department of origin, the patient's index condition, age at initial presentation, and number of signs/symptoms did not differ between women with and without a genetic diagnosis of NCCAH (data not shown). Twenty-six women (89.7%) received drug treatment for NCCAH at some point during follow-up, most frequently corticosteroids (23 women, 79.3%). Similarly, at 314 follow-up visits, 87.9% of the women were receiving drug treatment, most frequently corticosteroids (74.2%). Use of drug treatment did not differ in women with and without a genetic diagnosis of NCCAH (88.9 vs 90.9% at some point during follow-up, ns).
The main finding of this investigation is that a clinically significant subset of women followed and treated according to a diagnosis of NCCAH did not have a confirmatory genetic diagnosis. Some patients had been referred from other centers and access to lab tests at diagnosis and follow-up was limited. This could partly explain the less than optimal rate of available hormonal work-up at diagnosis. The limited sample size may have contributed to the non-significant differences in the characteristics of women with and without a genetic diagnosis of NCCAH.
All women included in this series presented symptoms suggestive of NCCAH together with at least an abnormal basal 17OHP at some point that could help understand the assignment of a NCCAH diagnosis. The heterozygote condition was not uncommon. In the literature, the clinical presentation and 17OHP values of the heterozygote carriers may overlap with that of NCCAH. 2 Other conditions, such as premature adrenarche in childhood or PCOS in young adults, might have been present. For example, Pall et al 5 reported an elevation of basal 17OHP in up to 25% of patients with PCOS.
Current guidelines emphasize limiting drug treatment to symptomatic NCCAH patients and avoiding corticosteroids whenever possible, with the exception of women seeking pregnancy. 3 At present we can only speculate on the potential untoward effects of prolonged treatment for a non-existing NCCAH.
The results of this audit compel us to reconsider the diagnostic and therapeutic requirements of patients coming to the outpatient clinic with an alleged diagnosis of NCCAH. The fact that a significant percentage of patients attended in different departments with a NCCAH diagnosis did not have a confirmatory genetic analysis suggests that the situation may not be uncommon.
